Evidence map›Paper›PMID 41729479›Full record

ArticleEuropean radiology experimental2026

Acquisition, image quality, and PI-RADS agreement of ultrahigh-gradient DWI in prostate 3-T MRI.

Leon M Bischoff, Christoph Endler, Philipp Krausewitz, Joerg Ellinger, Niklas Klümper, Alexander Isaak, Narine Mesropyan, Dmitrij Kravchenko, Daniel Kuetting, Alois M Sprinkart and 3 more

Abstract read
In one paragraph

Article in European radiology experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Leon M BischoffDepartment of Diagnostic and Interventional Radiology, University Hospital Bonn, Bonn, Germany.
Christoph EndlerDepartment of Diagnostic and Interventional Radiology, University Hospital Bonn, Bonn, Germany.
Philipp KrausewitzDepartment of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.
Joerg EllingerDepartment of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.
Niklas KlümperDepartment of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.
Alexander IsaakDepartment of Diagnostic and Interventional Radiology, University Hospital Bonn, Bonn, Germany.
Narine MesropyanDepartment of Diagnostic and Interventional Radiology, University Hospital Bonn, Bonn, Germany.
Dmitrij KravchenkoDepartment of Diagnostic and Interventional Radiology, University Hospital Bonn, Bonn, Germany.
Daniel KuettingDepartment of Diagnostic and Interventional Radiology, University Hospital Bonn, Bonn, Germany.
Alois M SprinkartDepartment of Diagnostic and Interventional Radiology, University Hospital Bonn, Bonn, Germany.
Petra MürtzDepartment of Diagnostic and Interventional Radiology, University Hospital Bonn, Bonn, Germany.
Claus C PieperDepartment of Diagnostic and Interventional Radiology, University Hospital Bonn, Bonn, Germany.
Julian A LuetkensDepartment of Diagnostic and Interventional Radiology, University Hospital Bonn, Bonn, Germany. julian.luetkens@ukbonn.de.ORCID http://orcid.org/0000-0002-7715-4636

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveNew magnetic resonance imaging (MRI) gradient technology enables the acquisition of ultrahigh b-value diffusion-weighted imaging (DWI). We assessed its impact on image quality and Prostate Imaging Reporting and Data System (PI-RADS) scores in prostate MRI. MATERIALS AND

methodsParticipants with cancer suspicion prospectively underwent 3-T prostate MRI (maximum gradient strength 200 mT/m). Sequences with b-values of 0/800, 1,500, 2,500, 3,500, and 4,500 s/mm² were acquired. Lesion conspicuity was rated from 1 (non-diagnostic) to 5 (excellent). Apparent signal-to-noise ratios (aSNR) and acquisition times were determined. Cumulative link mixed-effects models, repeated measures ANOVA, and Cohen/Fleiss κ statistics were used.

resultsA total of 107 participants, aged 67 ± 8 years (mean ± standard deviation), were included. Compared to DWI(b1500), the DWI(b2500), DWI(b3500), and DWI(b4500) acquisitions were worse regarding both lesion conspicuity (median score, 5 [interquartile interval 4-5] versus 4 [3-4] versus 2 [2-3] versus 2 [1-2], respectively; all p < 0.001) and aSNR (19.0 ± 7.5 versus 12.7 ± 4.8 versus 11.8 ± 4.1 versus 11.4 ± 2.6, respectively; all p < 0.001). Acquisition times increased from DWI(b1500) (107 ± 9 s) to DWI(b4500) (329 ± 26 s). Cohen κ for PI-RADS score agreement was good to moderate (DWI(b2500): 0.87 [confidence interval 0.81, 0.94]; DWI(b3500): 0.75 [0.65, 0.84]; DWI(4500): 0.61 [0.49, 0.72]).

conclusionAcquired ultrahigh gradient DWI sequences with ultrahigh b-values in prostate MRI had worse image quality than standard b-values, while PI-RADS agreement between DWI(b1500) and DWI(b2500) was good. However, diagnostic estimates for clinically significant prostate carcinoma remained limited due to a small biopsy sample size (50/107 patients). RELEVANCE STATEMENT: Ultrahigh b-value DWI showed no improved diagnostic performance in comparison to standard b-value DWI regarding the identification of potential prostate cancer. Ultrahigh b-value should not replace standard high b-values (1,500 s/mm²) for imaging workup of patients with suspicion for prostate cancer. KEY POINTS: Acquired ultrahigh b-values (b2500-4500) using ultrahigh gradients of up to 140 T/m were utilized for prostate DWI. Both, overall image quality and diagnostic confidence decreased from good for DWI(b1500) to non-diagnostic for DWI(b4500). PI-RADS agreement between DWI(b1500) and DWI(b2500) was good, while it was only moderate between DWI(b1500) and DWI(b4500).

Indexed as

Diffusion Magnetic Resonance ImagingProstateProstatic NeoplasmsAgedHumansMaleMiddle AgedProspective StudiesSignal-To-Noise RatioDiffusion magnetic resonance imagingMultiparametric magnetic resonance imagingPI-RADSProstateProstatic neoplasms

Identifiers

PMID41729479
PMCPMC12929734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.